BIOMAT Database Logo BIOMAT Database Logo

Cerebral ventricular enlargement and dopamine synthesis inhibition in chronic schizophrenia. 1980

H A Nasrallah, and J E Kleinman, and D R Weinberger, and J C Gillin, and R J Wyatt

UI MeSH Term Description Entries
D002552 Cerebral Ventricles Four CSF-filled (see CEREBROSPINAL FLUID) cavities within the cerebral hemispheres (LATERAL VENTRICLES), in the midline (THIRD VENTRICLE) and within the PONS and MEDULLA OBLONGATA (FOURTH VENTRICLE). Foramen of Monro,Cerebral Ventricular System,Cerebral Ventricle,Cerebral Ventricular Systems,Monro Foramen,System, Cerebral Ventricular,Systems, Cerebral Ventricular,Ventricle, Cerebral,Ventricles, Cerebral,Ventricular System, Cerebral,Ventricular Systems, Cerebral
D002908 Chronic Disease Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2). Chronic Condition,Chronic Illness,Chronically Ill,Chronic Conditions,Chronic Diseases,Chronic Illnesses,Condition, Chronic,Disease, Chronic,Illness, Chronic
D004351 Drug Resistance Diminished or failed response of an organism, disease or tissue to the intended effectiveness of a chemical or drug. It should be differentiated from DRUG TOLERANCE which is the progressive diminution of the susceptibility of a human or animal to the effects of a drug, as a result of continued administration. Resistance, Drug
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D012559 Schizophrenia A severe emotional disorder of psychotic depth characteristically marked by a retreat from reality with delusion formation, HALLUCINATIONS, emotional disharmony, and regressive behavior. Dementia Praecox,Schizophrenic Disorders,Disorder, Schizophrenic,Disorders, Schizophrenic,Schizophrenias,Schizophrenic Disorder
D014150 Antipsychotic Agents Agents that control agitated psychotic behavior, alleviate acute psychotic states, reduce psychotic symptoms, and exert a quieting effect. They are used in SCHIZOPHRENIA; senile dementia; transient psychosis following surgery; or MYOCARDIAL INFARCTION; etc. These drugs are often referred to as neuroleptics alluding to the tendency to produce neurological side effects, but not all antipsychotics are likely to produce such effects. Many of these drugs may also be effective against nausea, emesis, and pruritus. Antipsychotic,Antipsychotic Agent,Antipsychotic Drug,Antipsychotic Medication,Major Tranquilizer,Neuroleptic,Neuroleptic Agent,Neuroleptic Drug,Neuroleptics,Tranquilizing Agents, Major,Antipsychotic Drugs,Antipsychotic Effect,Antipsychotic Effects,Antipsychotics,Major Tranquilizers,Neuroleptic Agents,Neuroleptic Drugs,Tranquillizing Agents, Major,Agent, Antipsychotic,Agent, Neuroleptic,Drug, Antipsychotic,Drug, Neuroleptic,Effect, Antipsychotic,Major Tranquilizing Agents,Major Tranquillizing Agents,Medication, Antipsychotic,Tranquilizer, Major
D018492 Dopamine Antagonists Drugs that bind to but do not activate DOPAMINE RECEPTORS, thereby blocking the actions of dopamine or exogenous agonists. Many drugs used in the treatment of psychotic disorders (ANTIPSYCHOTIC AGENTS) are dopamine antagonists, although their therapeutic effects may be due to long-term adjustments of the brain rather than to the acute effects of blocking dopamine receptors. Dopamine antagonists have been used for several other clinical purposes including as ANTIEMETICS, in the treatment of Tourette syndrome, and for hiccup. Dopamine receptor blockade is associated with NEUROLEPTIC MALIGNANT SYNDROME. Dopamine Antagonist,Dopamine Blocker,Dopamine Receptor Antagonist,Dopamine Receptor Antagonists,Dopaminergic Antagonist,Dopaminergic Antagonists,Antagonists, Dopamine,Antagonists, Dopamine Receptor,Antagonists, Dopaminergic,Dopamine Blockers,Antagonist, Dopamine,Antagonist, Dopamine Receptor,Antagonist, Dopaminergic,Blocker, Dopamine,Blockers, Dopamine,Receptor Antagonist, Dopamine,Receptor Antagonists, Dopamine

Related Publications

H A Nasrallah, and J E Kleinman, and D R Weinberger, and J C Gillin, and R J Wyatt
Cerebral ventricular enlargement in chronic schizophrenia.
September 1988, The British journal of psychiatry : the journal of mental science,
H A Nasrallah, and J E Kleinman, and D R Weinberger, and J C Gillin, and R J Wyatt
Lateral cerebral ventricular enlargement in chronic schizophrenia.
July 1979, Archives of general psychiatry,
H A Nasrallah, and J E Kleinman, and D R Weinberger, and J C Gillin, and R J Wyatt
Cerebral ventricular enlargement in subtypes of chronic schizophrenia.
July 1982, Archives of general psychiatry,
H A Nasrallah, and J E Kleinman, and D R Weinberger, and J C Gillin, and R J Wyatt
Cerebral ventricular enlargement in chronic schizophrenia: consistencies and contradictions.
March 1987, The British journal of psychiatry : the journal of mental science,
H A Nasrallah, and J E Kleinman, and D R Weinberger, and J C Gillin, and R J Wyatt
Association between cerebral ventricular enlargement and suicide attempts in chronic schizophrenia.
March 1984, The American journal of psychiatry,
H A Nasrallah, and J E Kleinman, and D R Weinberger, and J C Gillin, and R J Wyatt
Cerebral ventricular enlargement and suicide in schizophrenia and mania.
July 1984, The American journal of psychiatry,
H A Nasrallah, and J E Kleinman, and D R Weinberger, and J C Gillin, and R J Wyatt
Cerebral ventricular enlargement in chronic schizophrenia. An association with poor response to treatment.
January 1980, Archives of general psychiatry,
H A Nasrallah, and J E Kleinman, and D R Weinberger, and J C Gillin, and R J Wyatt
Genetic risk for schizophrenia, birthweight, and cerebral ventricular enlargement.
November 1988, Journal of abnormal psychology,
H A Nasrallah, and J E Kleinman, and D R Weinberger, and J C Gillin, and R J Wyatt
Clinical and neuropsychological correlates of cerebral ventricular enlargement in schizophrenia.
January 1985, Journal of psychiatric research,
H A Nasrallah, and J E Kleinman, and D R Weinberger, and J C Gillin, and R J Wyatt
Seasonality of birth and ventricular enlargement in chronic schizophrenia.
June 1994, Psychiatry research,
Copied contents to your clipboard!